Literature DB >> 9040023

Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis.

S Pankuweit1, I Portig, F Lottspeich, B Maisch.   

Abstract

In myocarditis an antigen-specific immune response to cardiac epitopes has been demonstrated by several investigators. In 54 patients with histologically proven myocarditis, autoantibodies to cardiac tissue were observed in 73% of patients utilizing the indirect immunofluorescence test with human myocardium and adult heterologous cardiocytes. By immunoblot, 44% of sera from patients reacted with cardiac tissue. These antibodies were directed preferentially against proteins with the molecular weight of 43 up to 67 kDa. Three particular proteins were identified by the use of two-dimensional immunoblot and further characterized by amino acid sequence analysis. To characterize the epitopes recognized by the autoantibodies isoelectric focusing followed by SDS-PAGE was used to separate the complex mixture of proteins from human heart. Immunoblot analysis of antigens revealed proteins ranging from a size of 30-67 kDa at isoelectric points of 6.5-8.5 to be of particular interest. Five of these proteins have now been analyzed by N-terminal amino acid sequencing (Edman degradation). One was found to be creatine kinase and one was identified as a yet unknown protein. Three proteins were N-terminally blocked and were investigated further by enzymatical digestion, followed by separation of the usually complex peptide mixtures on HPLC. One of the peptides was found to be dihydrolipoamide dehydrogenase, a membrane enzyme, and one was identified as a sarcomere specific creatine kinase. Because these proteins are intracullularly located enzymes, their pathogenetic role as antigens for the autoantibodies remains to be elucidated further.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040023     DOI: 10.1006/jmcc.1996.0253

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

Review 1.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  [Coronary heart disease as inflammatory disease of the vascular bed? Etiology, sequela or misconception?].

Authors:  B Maisch
Journal:  Herz       Date:  1998-05       Impact factor: 1.443

3.  [Classification of cardiomyopathies according to the WHO/ISFC Task Force--more questions than answers?].

Authors:  B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 4.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

5.  Autoimmune markers are undetectable in end stage idiopathic dilated cardiomyopathy.

Authors:  N de Leeuw; W J Melchers; D J Ruiter; A L Caforio; A H Balk; N de Jonge; J M Galama
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 6.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 7.  Autoimmunological features in inflammatory cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Andrea Dörner; Wolfgang-Christian Poller; Michel Noutsias; Uwe Kühl; Heinz-Peter Schultheiss; Mathias Pauschinger
Journal:  Clin Res Cardiol       Date:  2007-05-22       Impact factor: 5.460

8.  Molecular Aspects of Myocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.663

Review 9.  Acute viral myocarditis.

Authors:  Robert Dennert; Harry J Crijns; Stephane Heymans
Journal:  Eur Heart J       Date:  2008-07-09       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.